A Clinical Lipidomics Platform: Development and Validation of a High-Throughput LC-MS Assay for Cardiovascular Disease Risk Assessment
A rapid blood lipid test predicts heart disease risk better than traditional scores, especially for intermediate-risk patients, and takes only six minutes to run.
This study validated a high-throughput 6-minute clinical lipidomics platform measuring 270 lipid species, demonstrating excellent correlation with a full research-grade platform and showing that the derived Lipidomic Risk Score outperforms the traditional Framingham Risk Score for cardiovascular risk prediction, particularly in intermediate-risk patients. The 6-minute assay runtime and automated processing address major barriers to clinical lipidomics adoption.
What the study was
- Study design
- Validation study (cohort-based, n=994; BioHEART-CT Discovery Cohort)
- Population
- Adults in BioHEART-CT Discovery Cohort (n=994)
- Sample size
- 994
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Analytical Chemistry
Why it surfaced
High-throughput clinical lipidomics platform with validated performance; addresses clinical scalability gap; Baker Heart Institute; outperforms established Framingham score in intermediate risk group.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.